Prevention of stomach cancer Cancer Gastric cancer
Conditions
Interventions
Participants seen in treatment weeks, if H. pylori positive, were offered a one week course of eradication therapy comprising twice-daily oral metronidazole 400 mg, clarithromycin 250 mg and lansopraz
Sponsors
Queen Mary University of London (UK)
Eligibility
Sex/Gender
All
Age
35 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1. Healthy NHS-registered UK residents 2. Male participants aged 35-69 3. Female participants aged 45-69 4. Patients attending a Bupa Wellness Centre for a health screen
Exclusion criteria
Exclusion criteria: 1. On medication which may interact dangerously with metronidazole, clarithromycin or lansoprazole (according to Appendix 1 of the British National Formulary) 2. A history of intolerance or allergy to metronidazole, clarithromycin or lansoprazole or other drugs of the same class as any of these three drugs 3. Currently being treated for an ulcer 4. On a proton-pump inhibitor or H2 antagonist 5. Having been tested or treated for H. pylori infection in the previous three years 6. Pregnancy or breastfeeding 7. Past history of or current gastric cancer 8. Life-threatening illness 9. Porphyria 10. Prolongation of QT interval 11. Current clinical liver disease or a history of severe liver disease
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence of and death from oesophageal cancer 2. Death from ischaemic heart disease 3. Death from gastric bleed or peptic ulcer | — |
Primary
| Measure | Time frame |
|---|---|
| Incidence of and death from stomach cancer | — |
Countries
England, United Kingdom
Outcome results
None listed